Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487
HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR development programLund, Sweden, October 9, 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487. Results showed the molecule was safe and well tolerated. Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects. Pharmacokinetics (PK) was in line with expectations and pharmacodynamics (PD) (